2026年美國癌症研究協會（AACR）年會發表重大癌症研究成果
Major cancer research findings unveiled at 2026 AACR meeting
2026年於聖地牙哥舉行的美國癌症研究協會（AACR）年會標誌著腫瘤學的重大飛躍。
The 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego marked a significant leap forward in oncology.
超過2萬2千名專家齊聚一堂，聚焦於精準醫療、合作與目標。
With over 22,000 experts gathering, the focus remained on precision, partnership, and purpose.
其中一項主要亮點是對早發型大腸癌（EOCRC）的研究，研究人員利用人工智慧發現這些腫瘤處於比晚發型病例更具免疫抑制的環境中。
A primary highlight was the study of Early-Onset Colorectal Cancer (EOCRC), where researchers utilized Artificial Intelligence to discover that these tumors operate in a more immunosuppressive environment than late-onset cases.
此外，免疫治療的進展揭示了NAT10-MYC路徑如何導致耐藥性，為治療提供了新的標靶。
Furthermore, advancements in immunotherapy revealed how the NAT10-MYC pathway contributes to drug resistance, offering new targets for treatment.
在臨床應用方面，抗體藥物偶聯體（ADC）trastuzumab deruxtecan相較於傳統化學治療，對特定轉移性癌症展現出更優越的存活率。
In clinical applications, the antibody-drug conjugate trastuzumab deruxtecan demonstrated superior survival outcomes for specific metastatic cancers compared to traditional chemotherapy.
這些發現架起了基礎實驗科學與現實世界臨床應用之間的橋梁，為未來更加個人化的癌症照護帶來了希望。
These findings bridge the gap between basic laboratory science and real-world clinical application, promising a more personalized approach to future cancer care.
